MedTrace Logo

Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study

NCT02211482 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-08-14

No results posted yet for this study

Summary

The purpose of this study is to evaluate the antiviral efficacy, safety and tolerability of dual therapy with 3TC and DTG as initial therapy among naïve HIV patients

Conditions

  • HIV-1 Infection

Interventions

DRUG

dolutegravir, lamivudine

single arm

Sponsors & Collaborators

  • ViiV Healthcare

    collaborator INDUSTRY

  • Fundación Huésped

    lead OTHER

Principal Investigators

  • Pedro Cahn, PhD · Fundacion Huesped

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2016-03-31
Completion
2017-04-30

Countries

  • Argentina

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02211482 on ClinicalTrials.gov